Faster Answers, Better Decisions: ADLM 2026 Highlights

QuidelOrtho (Nasdaq: QDEL) released episode 60 of its Science Bytes podcast, highlighting key themes from the 2026 Association for Diagnostics and Laboratory Medicine (ADLM) Annual Conference.

Rhea-AI Summary

QuidelOrtho (Nasdaq: QDEL) released episode 60 of its Science Bytes podcast, highlighting key themes from the 2026 Association for Diagnostics and Laboratory Medicine (ADLM) Annual Conference. Host Stephanie Kleewein speaks with experts from LEX Diagnostics, Thermo Fisher Scientific and QuidelOrtho about innovations in molecular diagnostics, antibiotic stewardship and cardiovascular assessment.

Key insights include ultra-fast RT-PCR delivering respiratory results in as little as six minutes, simplified workflows that support near-patient and CLIA‑waived molecular testing, the use of procalcitonin (PCT) to guide antibiotic use with reported reductions in antibiotic exposure and adverse events, and high-sensitivity troponin testing to speed evaluation of suspected cardiac events. According to QuidelOrtho, these advances aim to give clinicians rapid, actionable information to improve emergency department flow, decision-making and patient outcomes.

Argus Aug 27 session 7 alerts

+2.75% close to close 1.0x rel. volume Open Argus

Details

News Market Reaction – QDEL

-8.5% Trough in 4 hr 56 min

$1.10B Market Cap

On Aug 27, the day this news came out, QDEL closed 2.75% above the previous close. Argus tracked a trough of -8.5% from its starting point during tracking. Our momentum scanner recorded 7 alerts in the available session data.

Data tracked by StockTitan Argus for the Aug 27 session.

Key Figures

Podcast Episode: 60 Conference Year: 2026 Presentations: 3 presentations +2 more

Podcast Episode

60

Science Bytes podcast

Conference Year

2026

ADLM Annual Conference

Presentations

3 presentations

Podcast episode highlights

Respiratory Test Results

6 minutes

Ultra-fast RT-PCR technology

Complete Test Results

less than 10 minutes

Ultra-fast RT-PCR technology

Historical Context

5 past events · Latest: Aug 06

5 events

1. Aug 06

   Q2 earnings report

   24h Move

   -24.7%

   Lowered full-year revenue and EBITDA guidance; withdrew free cash flow guidance.

2. Jul 24

   Q2 earnings date

   24h Move

   -3.2%

   Announced the August 6 financial-results reporting date and conference call.

3. Jul 23

   Podcast release

   24h Move

   -0.6%

   Released episode 59 discussing evolving overdose risks and toxicology testing.

4. Jul 15

   Inducement grant

   24h Move

   +0.1%

   Approved restricted stock units covering 356,555 common shares for the CFO.

5. Jun 23

   Leadership change

   24h Move

   -3.5%

   Appointed Micah Young CFO effective July 6, succeeding the retiring CFO.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

rt-pcr, clia-waived, procalcitonin, high-sensitivity troponin

4 terms

rt-pcr technical

"Ultra-fast RT-PCR technology can deliver respiratory test results"

RT-PCR is a laboratory test that converts a tiny amount of genetic material from a sample into many copies so specific viral or genetic targets can be detected, like photocopying one page until you have enough to read clearly. For investors, RT-PCR matters because its accuracy, capacity, and regulatory approval drive demand for diagnostic equipment, testing services, and related supply chains, and can influence revenue and market sentiment around healthcare and biotech companies.

clia-waived regulatory

"near-patient and CLIA-waived settings"

A CLIA-waived test is a diagnostic test designated under U.S. Clinical Laboratory Improvement Amendments rules as simple to perform and with a low risk of producing incorrect results; many are cleared by the FDA for use outside specialized labs. Think of it like a home appliance versus industrial machinery: it can be run in doctor’s offices, pharmacies, or at home with minimal training and oversight. For investors, the designation matters because it broadens where the test can be sold and used, affecting potential market size, distribution channels, and regulatory costs.

procalcitonin medical

"Procalcitonin (PCT) provides clinicians with a reliable biomarker"

A peptide produced in the body that becomes elevated in the blood during systemic bacterial infections and sepsis, used clinically as a diagnostic biomarker to help detect and track bacterial inflammation. Think of it like a smoke detector for bacterial infection: its level helps clinicians distinguish bacterial causes from nonbacterial illnesses. Its commercial and regulatory importance stems from use in diagnostic tests, laboratory services, clinical decision algorithms, and related reimbursement and approval pathways.

high-sensitivity troponin medical

"High-sensitivity troponin testing enables faster assessment"

A high-sensitivity troponin test measures very small amounts of a protein released into the blood when heart muscle is injured. Acting like a sensitive smoke alarm for the heart, it helps doctors detect heart attacks earlier, estimate a patient’s short-term risk, and guide treatment decisions; for investors, shifts in test use, accuracy, or regulation can influence makers of diagnostic tests, hospital spending, and related medical markets.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN DIEGO, Aug. 27, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL), a leading global provider of diagnostic solutions, has released episode 60 of its Science Bytes podcast, featuring highlights from the 2026 Association for Diagnostics and Laboratory Medicine (ADLM) Annual Conference.

Hosted by Stephanie Kleewein, the special episode showcases three presentations addressing some of healthcare's most pressing challenges: delivering faster molecular diagnostic results, improving antibiotic stewardship and accelerating cardiovascular assessment.

Featured guests include Dr. Heather Danks, Chief Technology Officer at LEX Diagnostics; Dr. Mike Broyles, Director of Medical Affairs for Biomarkers at Thermo Fisher Scientific; and Dr. Lindy Carlstrom, Medical Affairs Manager at QuidelOrtho. Together, they discuss how innovation is helping clinicians gain faster, more actionable insights when time matters most.

Key Insights:

• Ultra-fast RT-PCR technology can deliver respiratory test results in as little as six minutes and complete results in less than 10 minutes
• Simplified workflows are helping expand molecular testing into near-patient and CLIA-waived settings
• Procalcitonin (PCT) provides clinicians with a reliable biomarker to support antibiotic stewardship and reduce unnecessary antibiotic use
• Real-world PCT implementation has been associated with reductions in antibiotic exposure, readmissions and adverse events
• High-sensitivity troponin testing enables faster assessment of patients presenting with suspected cardiac events
• Advances in diagnostic precision are helping emergency departments improve patient flow and support timely clinical decisions

Across molecular diagnostics, infectious disease management and cardiovascular care, the conversation highlights a common goal: providing clinicians with rapid, actionable information that supports confident decision-making and better patient outcomes.

Listen to the latest episode of the QuidelOrtho Science Bytes podcast on major streaming platforms or at https://www.quidelortho.com/global/en/resources/podcasts/quidelortho-science-bytes.

About QuidelOrtho Corporation
With expertise spanning clinical chemistry, immunoassay, immunohematology and molecular testing, QuidelOrtho Corporation (Nasdaq: QDEL) is a leading global provider of diagnostic solutions, dedicated to advancing fast, accurate and reliable results that help improve patient outcomes – from the point of care to hospital, lab to clinic. Building on a legacy of innovation, QuidelOrtho works with healthcare providers to advance diagnostics that connect insights with solutions, defining a clearer path for informed decisions and better care.

Investor Contact:
Juliet Cunningham
Vice President, Investor Relations
IR@QuidelOrtho.com 

Media Contact:
Stephanie Kleewein
Senior Corporate Communication and PR Manager
media@QuidelOrtho.com 

View original content to download multimedia:https://www.prnewswire.com/news-releases/faster-answers-better-decisions-adlm-2026-highlights-302861038.html

SOURCE QuidelOrtho Corporation

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What is the focus of QuidelOrtho’s Science Bytes episode 60 related to ADLM 2026 (QDEL)?

Episode 60 focuses on highlights from the 2026 ADLM Annual Conference, emphasizing faster diagnostics and better clinical decisions. According to QuidelOrtho, experts discuss innovations in molecular testing, antibiotic stewardship and cardiovascular assessment that aim to deliver rapid, actionable information when time is critical.

How fast can the ultra-fast RT-PCR technology discussed by QuidelOrtho deliver results in ADLM 2026 highlights?

The ultra-fast RT-PCR technology discussed can provide respiratory test results in as little as six minutes. According to QuidelOrtho, complete results may be available in less than 10 minutes, supporting quicker clinical decisions and expanding molecular diagnostics into near-patient and CLIA‑waived settings.

How does procalcitonin (PCT) support antibiotic stewardship in QuidelOrtho’s ADLM 2026 podcast (QDEL)?

Procalcitonin (PCT) is presented as a biomarker that helps clinicians guide antibiotic use more appropriately. According to QuidelOrtho, real-world PCT implementation has been associated with reduced antibiotic exposure, fewer readmissions and fewer adverse events, supporting antibiotic stewardship programs in clinical practice.

What role does high-sensitivity troponin play in cardiovascular assessment discussed by QuidelOrtho (QDEL)?

High-sensitivity troponin testing is described as enabling faster assessment of patients with suspected cardiac events. According to QuidelOrtho, this diagnostic advance supports more timely clinical decisions and can help emergency departments improve patient flow and overall cardiovascular care pathways.

Where can investors and clinicians listen to QuidelOrtho’s Science Bytes episode 60 on ADLM 2026?

Listeners can access episode 60 of Science Bytes on major streaming platforms or via QuidelOrtho’s website. According to QuidelOrtho, the episode is available at its dedicated podcast page, offering detailed discussions on ADLM 2026 diagnostic innovations.

Which experts are featured in QuidelOrtho’s ADLM 2026 Science Bytes episode (QDEL)?

The episode features Dr. Heather Danks from LEX Diagnostics, Dr. Mike Broyles from Thermo Fisher Scientific, and Dr. Lindy Carlstrom from QuidelOrtho. According to QuidelOrtho, they discuss innovations in ultra-fast RT-PCR, PCT-guided antibiotic stewardship and high-sensitivity troponin testing.